Logo

People in the News: Dec 23, 2010 (rev. 2)

Dec 23, 2010
Premium

Rosetta Genomics said Brian Markison has been named an observer of the company's board.

Pending shareholder approval, he will also become a director, the firm said.

Markison is currently chairman and CEO of King Pharmaceuticals, which was recently acquired by Pfizer. Previously, he held a variety of roles at Bristol-Myers Squibb, including president of oncology/virology and oncology therapeutics.

Filed under

Gene Editing, Gene Silencing, & CRISPR
RNAi
miRNA
Rosetta Genomics
Breaking News
The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.